Filled Buprenorphine Prescriptions for Opioid Use Disorder During COVID-19 Pandemic

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, DECEMBER 21, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.7497?guestAccessKey=ef436ecf-e2b4-4df0-adfe-d8a288640c59&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122120

 

What The Study Did: The COVID-19 pandemic has disrupted health care delivery in the United State, and researchers in this study examined changes in total U.S. retail pharmacy sales and sales of buprenorphine products with a U.S. Food and Drug Administration–approved indication for treat- ment of opioid use disorder.

Authors: Thuy D. Nguyen, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.

 

(doi:10.1001/jamainternmed.2020.7497)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.